Browse studies

Find your next paid study

27,295 recruiting studies available now

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Solid Tumors With KRAS G12V Mutations

This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T …

Non-small Cell Lung CancerPancreas CancerColon Cancer

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06043713

Phase 2

Phase II Trial of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is …

AdenocarcinomaProstate CancerNeoplasms+3 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07574541

Observational

6-Hz Primed Low and High-Frequency Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Children With Cerebral Palsy: TMS-EEG Study

This project examines the use of repetitive transcranial magnetic stimulation (rTMS) as a therapeutic approach to improve motor function in children with cereb…

Cerebral PalsyTypically Developing Children

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Cook Children's Health Care SystemNCT07567053

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other c…

Bladder CancerRecurrent Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)

Estimated

~$10 – $750

Actual pay is set by the research site.

University of WashingtonNCT07225127

Observational

Chatbot Utilization for Pedigree Creation and Cancer Risk Assessment in Cancer Genetic Counseling

This clinical trial studies whether a chatbot can be used to help collect medical history and perform cancer risk assessment among patients undergoing cancer g…

Hereditary Breast CarcinomaHereditary Malignant Neoplasm

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07887620

Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease and Related Inflammatory Conditions

Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditi…

Still's Disease, Adult-OnsetSystemic InflammationArthritis+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT03510442

Phase 3

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading th…

Diffuse Large B-Cell Lymphoma

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT06717347

Phase 2

A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-3…

Recurrent PericarditisHeart DiseasesPericarditis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Kiniksa Pharmaceuticals International, plcNCT07288216

An Observational Study of Natural Disease Progression in Participants With Macular Dystrophies Expressing a Stargardt-type Clinical Presentation

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the …

Stargardt DiseaseStargardt Macular DystrophyStargardt-like Macular Dystrophy

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07425574

Observational

PrEcision Pacing in HFpEF: the PEP-HFpEF Trial

The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with pr…

Heart Failure and Preserved Ejection FractionHeart Failure New York Heart Association Class IIIHeart Failure New York Heart Association (NYHA) Class II

Estimated

~$10 – $750

Actual pay is set by the research site.

Tufts Medical CenterNCT07864558

Phase 2

A Pilot Study to Estimate Early Clinical Efficacy Signals of a Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) Administration in Conjunction With Levonorgestrel Intrauterine Device (LNG-IUD) in Obese Patients With Endometrioid Intraepithelial Neoplasia

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients wit…

Endometrioid Endometrial Adenocarcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of FloridaNCT07107334

Phase 2

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen…

Core Binding Factor Acute Myeloid Leukemia

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06917911